Gender | ||||
---|---|---|---|---|
Characteristics | All (n = 60) | Female (n = 30) | Male (n = 30) | P = value |
Age (Years) | 36.9 | |||
CD4+ count (cells/mm3) | ||||
Mean | 230 | 207 | 243 | |
Range | (1-628) | (5-584) | (1-628) | |
<100 | 6 | 9 | P > 001 | |
101-200 | 13 | 8 | ||
201-300 | 1 | 3 | ||
301-400 | ||||
401-500 | 4 | 5 | ||
>600 | 2 | 1 | ||
WHO Disease staging | P > 001 | |||
WHO Stage 1 | 9 | 7 | 2 | |
WHO Stage 2 | 23 | 11 | 12 | |
WHO Stage 3 | 24 | 12 | 12 | |
WHO Stage 4 | 4 | - | 4 | |
Unstructured treatment interruptions | 39 | |||
Switch ART | 25 | |||
Mean duration since infected (Months) | 6.91 yrs | |||
First-line | 42 | 21 | 21 | |
Second-line | 18 | 9 | 9 | |
Education levels | ||||
Primary | 14 | 8 | 6 | P > 0.001 |
secondary | 22 | 9 | 13 | |
College/Tertiary | 21 | 8 | 13 | |
None | 2 | 1 | 1 | |
Marital status | ||||
Single | 5 | 3 | 2 | P > 0.841 |
Married | 49 | 20 | 29 | |
Separated/Divorced | 5 | 4 | 1 | |
Age groups | 21-30 | 4 | 5 | P >0.001 |
31-40 | 13 | 12 | ||
41-50 | 10 | 11 | ||
51-60 | 2 | 1 | ||
61-70 | 1 | |||
Sub-Total | 30 | 34 |